Tivozanib Versus Sorafenib as Initial Targeted Therapy for Patients With Advanced Renal Cell Carcinoma: Results From a Phase III Randomized, Open-Label, Multicenter Trial

摘要

Robert J. Motzer, MD, reported initial results from a randomized, multicenter, international, open-label, phase III trial comparing the anti-angiogenic agents tivozanib and sorafenib in patients with advanced RCC.1 Tivozanib is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. The drug's half-life of 3.7-4.7 days is designed to optimize blockade while minimizing off-target toxicity. Its pharmacoki-netic profile allows once-daily dosing.